Outsourcing

The financial crisis could lead to consolidation in the contract services industry.

Brief pharmaceutical news items for February 2009.

Dire circumstances are driving major drug companies to seek out CRO partners. This article contains bonus online-exclusive material.

A recent reader poll focused on predictions for the industry's future.

The Romanian pharmacetuical market has grown significantly in recent years, but with stagnation on the horizon, a path forward is needed.

FDA's role should not be overlooked as it has been in years past.

The European dose CMO sector appears to be very vibrant, probably more so than the market in the US.

Also, UCB will divest certain business in emerging markets to GSK; the KineMatik Group named Michael G. Jarjour president and CEO; more...

Also, Elan explores strategic alternatives; NanoGuardian appoints John D. Glover to lead its Security Advisory Board; more...

The US Food and Drug Administration issued its Draft Guidance for Industry on Submission of Laboratory Packages by Accredited Laboratories.

An integrated information technology environment can help pharmaceutical companies find new processes and approaches to improve manufacturing efficiency, productivity, and quality.

Also, Bristol-Myers Squibb forms collaboration with ZymoGenetics, Hana Biosciences appoints VP of regulatory affairs, more...

Also, Novozymes Biologicals settles pollution case with the US Department of Justice; EntreMed restructures management team; more...

Outsourcing sterile manufacturing involves an integrated approach in product life-cycle management.

Although its domestic market is on the rise, Pakistan's market conditions have not proved welcoming enough to keep foreign investors.

The financial crisis could lead to consolidation in the contract services industry.

The incoming administration has renewed hope for stem cells, but less adequate copycats may follow.

After a year of increased attention on the pharmaceutical supply chain in Asia, what will be the region's short- and long-term role? This article contains bonus online-exclusive material.

Brief pharmaceutical news items for January 2009.

Instead of hampering progress, cost pressures might inspire Big Pharma to get creative.

Leading professionals join the community of experts panel of Sourcing and Management.

Jim Miller's presentation at the 2008 AAPS Annual Meeting provides insight into outsourcing solutions.

How will the world's dominant pharmaceutical market fare under the new US president?

Also, Crucell and DSM announce deals with GSK, Talecris, and CSL; Nobel Prize winner Luc Montagnier joins Viral Genetics; more...

Also, BASF opens lab in Mumbai; Evotek president and CEO to resign; more...

Also, NicOx and DSM make manufacture and supply pact for naproxcinod drug substance; NovaRx appointed Norrie Russell president and COO; more...

A Centers for Disease Control and Prevention (CDC) study confirmed that severe adverse reactions reported in the fall and winter of 2007 resulted from heparin contaminated with oversulfated chondroitin sulfate (OSCS).

The Synthetic Chemical Organic Manufacturers Association (SOCMA) has raised concerns over requirements for security vulnerability assessments (SVA) under the US Department of Homeland Security's (DHS) Chemical Facility Anti-Terrorism Act Standards (CFATS).

Industry experts are predicting that last week?s terror attacks in Mumbai, India may have at minimum some short-term effects on the pharmaceutical industry outsourcing business in that region.

Also, AstraZeneca announces changes to its supply chain operations; Christian Velmer appointed head of Wyeth Canada; More...